HIV/AIDS Immunoassay Diagnostics Market Growing at a CAGR Of ~5% and to Target ~US$ 870 Million By 2027 | Transparency Market Research

According to the report, the global HIV/AIDS immunoassay diagnostics market was valued at ~US$ 550 Mn in 2018 and is projected to expand at a CAGR of ~5% from 2019 to 2027.

𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

• Human immunodeficiency virus (HIV) belongs to the retrovirus family. HIV is transmitted through unprotected sex with an infected person, transfusion of HIV infected blood, and sharing needles contaminated with HIV infected blood.
• Rise in prevalence of HIV across the globe, HIV infections among young population, blood donations, awareness about HIV diagnosis across the globe, and favorable initiatives by governments for HIV/AIDS diagnosis and prevention are key factors that are anticipated to drive the global HIV/AIDS immunoassay diagnostics market during the forecast period
• North America held a major share of the global HIV/AIDS immunoassay diagnostics market in 2018. It is primarily driven by factors such as presence of key market players, highly structured health care industry, and key developments by market players such as product launch approvals, key mergers, and acquisitions.
• The HIV/AIDS immunoassay diagnostics market in Asia Pacific is expected to expand at a high CAGR of ~7% from 2019 to 2027. Increase in the number of people with sexually transmitted diseases, rise in incidence of HIV infection among young adults, product approvals, and rise in awareness about HIV/AIDS diseases are factors anticipated to fuel the growth of the HIV/AIDS immunoassay diagnostics market in the region.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74619

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐇𝐈𝐕 𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐞 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

• HIV is basically transmitted through unprotected sex with an infected person, transfusion of HIV infected blood, and sharing needles contaminated with HIV infected blood. Rise in the number of patients with HIV contamination at an alarming rate in several countries is a major factor likely to drive the revenue of a large number of diagnostic labs and clinics in the near future.
• According to the WHO, HIV continues to be a major global public health issue. Based on UNAIDS report 2018, 39.6 million adults and children were living with HIV and approximately 940,000 individuals died from HIV globally.
• Approximately 1.7 million people were newly infected with HIV globally, in 2018
• Majority of the affected population lives in lower and middle-income countries. Middle East & Africa and Asia Pacific have high incidence rate of HIV infections across the globe.
• Hence, rise in prevalence of HIV is projected to increase the demand for HIV diagnostics which, in turn, is anticipated to boost the growth of the market
• According to HIV.org, approximately 1.1 million people in the U.S. were living with HIV in 2018
• According to Avert.org, approximately 2.2 million people in Western Europe were living with HIV infections in 2018. Moreover, Eastern Europe witnessed a 29% increase in new HIV infections annually between 2010 and 2018.

𝐊𝐢𝐭𝐬 & 𝐑𝐞𝐚𝐠𝐞𝐧𝐭𝐬 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞𝐝 𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

• In terms of product, the global HIV/AIDS immunoassay diagnostics market can be classified into analyzers and kits & reagents
• The kits & reagents segment dominated the global HIV/AIDS immunoassay diagnostics market in 2018 and the trend is projected to continue during the forecast period. Several key market players are investing in the expansion of their assay offerings. Leading market players offer more than 100 tests across different application areas using the CLIA technology. Moreover, low cost and short test time are likely to propel the segment during the forecast period.

𝐂𝐋𝐈𝐀 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐭𝐨 𝐋𝐞𝐚𝐝 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

• In terms of technology, the global HIV/AIDS immunoassay diagnostics market has been segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and others (immunofluorescent assay (IFA), radioimmunoassay (RIA), and enzyme-linked fluorescent assay (ELFA)). The chemiluminescence immunoassay (CLIA) segment accounted for majority of the market share in 2018. The segment is projected to register the highest market attractiveness index by 2027. High sensitivity of the CLIA technology and its ability to detect HIV-1 and HIV-2 antibodies and p24 antigen separately, which is useful in the early diagnosis of HIV infections, is anticipated to drive the segment. Moreover, availability of a wide range of assays and high throughput of CLIA analyzers are likely to propel the segment from 2019 to 2027.
• The ELISA segment is anticipated to expand at a rapid CAGR during the forecast period. ELISA is considered as the gold standard technique and a screening tool for HIV infections.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=74619<ype=S

𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 𝐭𝐨 𝐅𝐥𝐨𝐮𝐫𝐢𝐬𝐡 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

• In terms of end user, the global HIV/AIDS immunoassay diagnostics market has been categorized into hospitals, diagnostic laboratories, blood banks, and others
• The diagnostic laboratories segment held a major share of the global HIV/AIDS immunoassay diagnostics market in 2018. Growth of the segment can be attributed to the increase in incidence rate of HIV infections leading to high demand for early disease diagnosis. Moreover, high-volume consumption of immunoassay reagents and test kits such as ELISA and CLIA in diagnostic laboratories for the diagnosis of HIV infections is expected to boost the growth of the segment.

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭; 𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐭𝐨 𝐎𝐟𝐟𝐞𝐫 𝐒𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐈𝐧𝐜𝐫𝐞𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲

• In terms of region, the global HIV/AIDS immunoassay diagnostics market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held a major share of the global HIV/AIDS immunoassay diagnostics market in 2018. It is primarily driven by factors such as presence of key market players, highly structured health care industry, and key development by market players such as product launch approvals, key mergers, and acquisitions.
• In May 2016, DiaSorin and Beckman Coulter signed an agreement for the promotion and distribution of DiaSorin's hepatitis (A, B, and C) and HIV tests on DiaSorin's Liaison XL platform in the U.S.
• In October 2017, Siemens Healthineers launched its new, integrated, automated immunoassay and chemistry analyzer 'Atellica'. This move is estimated to attract more consumers toward complete laboratory automation and integration. Moreover, high awareness of HIV/AIDS disease among people is leading to the adoption of new therapy for diagnosis of HIV/AIDS. This factor is anticipated to drive the HIV/AIDS immunoassay diagnostics market in the region
• The HIV/AIDS immunoassay diagnostics market in Asia Pacific is projected to grow at a rapid pace in the near future. India, China, and Australia are expected to be lucrative markets, owing to setting up of new diagnostic laboratories and rise in awareness about the benefits of diagnosis of HIV using kits, reagents, and assays. For instance, in June 2017, Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) received approval from the U.S. FDA for its automated immunoassay analyzer 'Maglumi 2000', becoming the first China-based manufacturer to receive this approval. This product approval is expected to enable the company to enhance its product portfolio and strengthen its market position in China.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

• Key players operating in the global HIV/AIDS immunoassay diagnostics market are F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Siemens Healthineers AG, DiaSorin S.p.A., Abbott Laboratories, Ortho Clinical Diagnostics (a part of Carlyle Group), Shenzhen New Industries Biomedical Engineering Co., Ltd., bioMérieux SA, and Fujirebio (Miraca Group)
• These companies engage in research & development activities to develop novel products in order to expand product offerings and customer base. For instance, in June 2017, Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) received approval from the U.S. FDA for its automated immunoassay analyzer 'Maglumi 2000', becoming the first China-based manufacturer to receive this approval. In June 2016, Ortho Clinical Diagnostics received the CE Mark approval for its Vitros HIV combo test, which can be used in its VITROS series of automated immunoassay analyzers. This has expanded the company's portfolio in infectious disease assays.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=74619

𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭

Analyzers
Kits & Reagents

𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲

Enzyme-linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Others
Immunofluorescent Assay (IFA)
Radioimmunoassay (RIA)
Enzyme-linked Fluorescent Assay (ELFA)

𝐇𝐈𝐕/𝐀𝐈𝐃𝐒 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫

Hospitals
Diagnostic Laboratories
Blood Banks
Others

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐔𝐫𝐢𝐧𝐚𝐫𝐲 𝐂𝐚𝐭𝐡𝐞𝐭𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.einpresswire.com/article/576040433/urinary-catheters-market-size-is-expected-to-reach-us-5-1-billion-and-growing-at-4-5-cagr-by-2028

𝐃𝐍𝐀 𝐓𝐞𝐬𝐭 𝐊𝐢𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.globenewswire.com/news-release/2022/04/13/2421920/0/en/DNA-Test-Kits-Market-to-Cross-US-2-7-Bn-Mark-by-2030-TMR-Report.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.